Longevity covers therapeutics, robotics, and fintech. Yet as an emerging industry how do these get financed when they are so risky? How should venture firms evaluate longevity companies and how should founders attract investors and employees? This course will look at these questions specifically as applied to longevity, uniquely from the investor, scientist, and the founder viewpoint. After providing a foundation to the field we will interact with guest lectures from investors, scientists and company founders who can explain their respective perspectives. The course will cover finance and science aspects of longevity though no pre-requisites are expected.
2-3 units · Medical Option (Med-Ltr-CR/NC)
Longevity covers therapeutics, robotics, and fintech. Yet as an emerging industry how do these get financed when they are so risky? How should venture firms evaluate longevity companies and how should founders attract investors and employees? This course will look at these questions specifically as applied to longevity, uniquely from the investor, scientist, and the founder viewpoint. After providing a foundation to the field we will interact with guest lectures from investors, scientists and company founders who can explain their respective perspectives. The course will cover finance and science aspects of longevity though no pre-requisites are expected.
Offered in Spring 2027 at Stanford University.